Preclinical Therapy
Preclinical Therapy - Related Videos
06:38
A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
0 Views •
Cited by 23 •
2017
Implementation of an orthotopic model of renal cell carcinoma in immunocompetent mice affords the investigator a clinically-relevant system defined by the presence of a primary renal tumor and lung metastases in the same animal. This system can be used to preclinically test a variety of treatments in vivo.
09:34
An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
0 Views •
Cited by 4 •
2021
Rapid and efficient quantification of intracellular M. tuberculosis growth is crucial for pursuing improved therapies against tuberculosis (TB). This protocol describes a broth-based colorimetric detection assay using an automated liquid culture system to quantify Mtb growth in macrophages treated with candidate host-directed therapies.
06:51
A Preclinical Murine Model of Hepatic Metastases
0 Views •
Cited by 119 •
2014
A preclinical, murine model of hepatic metastases performed via a hemispleen injection technique.
09:29
Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
0 Views •
Cited by 23 •
2016
Utilizing patient-derived tumors in a subcutaneous preclinical model is an excellent way to study the efficacy of novel therapies, predictive biomarker discovery, and drug resistant pathways. This model, in the drug development process, is essential in determining the fate of many novel anti-cancer therapies prior to clinical investigation.
08:45
Cerenkov Luminescence Imaging (CLI) for Cancer Therapy Monitoring
0 Views •
Cited by 8 •
2012
Use of Cerenkov Luminescence Imaging (CLI) for monitoring preclinical cancer treatment is described here. This method takes advantage of Cerenkov Radiation (CR) and optical imaging (OI) to visualize radiolabeled probes and thus provides an alternative to PET in preclinical therapeutic monitoring and drug screening.
FAQs
Mechanistic assessment asks whether a candidate changes the biological target associated with the tumor response, rather than merely reducing tumor burden. Investigators examine target inhibition alongside downstream evidence of tumor-cell death, allowing them to connect molecular activity with an observed treatment effect. This linkage helps distinguish a treatment that acts through its intended mechanism from one whose activity requires further clarification.
Drug exposure, dose, and delivery are interpreted together because antitumor activity must be considered alongside how much treatment reaches the model and what toxicity appears. Preclinical studies therefore examine whether a candidate can achieve relevant exposure while toxicity is characterized and whether delivery considerations alter the result. These findings inform regimen refinement before clinical development.
Combination regimens are evaluated to determine whether pairing treatments produces a more informative therapeutic response than assessing a single agent alone. The analysis can relate combined treatment to target inhibition, tumor-cell death, exposure, and toxicity. In cancer research, this approach helps refine therapeutic design and prioritize combinations whose biological activity and safety findings justify additional development.
Assessment may include testing a drug, biologic, or combination regimen in cultured tumor cells, followed by evaluation in tumor-bearing models. Across these systems, investigators examine biological activity, target inhibition, tumor-cell death, drug exposure, and toxicity. Comparing molecular responses with treatment outcomes provides a broader basis for judging efficacy and identifying issues that require refinement.
Decision-making centers on whether the candidate demonstrates sufficient antitumor efficacy and what toxicity is observed in the tested models. Investigators also consider dose and delivery information because these factors shape further development. Together, the results help determine whether to advance a candidate, refine its design, or prioritize it for clinical development.
These studies support patient-focused research by linking molecular responses to treatment outcomes before human testing begins. In cancer research, that connection can help investigators select more promising drugs, biologics, or combinations and focus later development on approaches with evidence of biological activity, antitumor effect, and characterized toxicity. The result is a more informed path toward clinical evaluation.